US FDA Scrutizes Process Risks After Finding Nitrosamines In ARBs
Executive Summary
There is a new focus in reviews and inspections where nitrosamines or other dangerous process-related impurities might form.
You may also be interested in...
US FDA Postmarketing Drug Safety Modernization Plan Will Cut Across Review Disciplines
Detection of nitrosamine impurities in some marketed drugs highlights need for standardized, consistent approach to systematically monitor risks of drugs throughout their lifecycles, CDER’s Janet Woodcock says. Safety monitoring overhaul is lagging behind new drug review modernization effort, but implementation is expected to begin in 2020.
FDA: Key FY 2019 Warning Letter Trend Is Inadequate Testing For API Impurities
This year’s 89 warning letters so far hit API testing for nitrosamines, aseptic facility design, contaminated water, API traceability and more.
Contamination In Common OTC Antacid Adds To FDA's API Impurity Concerns
FDA assessing contamination of Rx and OTC H2 blocker ranitidine to determine steps it should take. The contaminant, NDMA, is dangerous when consumed in large quantities, but has been found in H2 blockers at levels that don't pose a risk, FDA says.